Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD

Nicola A. Hanania, Glenn D. Crater, Andrea N. Morris, Amanda H. Emmett, Dianne M. O'Dell, Dennis E. Niewoehner

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Background: Combining maintenance medications with different mechanisms of action may improve outcomes in COPD. In this study we evaluated the efficacy and safety of fluticasone/salmeterol (FSC) (250/50 mcg twice daily) when added to tiotropium (18 mcg once daily) (TIO) in subjects with symptomatic moderate to severe COPD. Methods: This was a 24-week, randomized, double-blind, parallel group, multi-center study. Subjects 40 years or older with cigarette smoking history ≥10 pack-years and with the diagnosis of COPD and post-bronchodilator FEV 1 ≥40 to ≤ 80% of predicted normal and FEV 1/FVC of ≤0.70 were enrolled. Following a 4-week treatment with open-label TIO 18 mcg once daily, subjects were randomized in a double-blind fashion to either the addition of FSC 250/50 DISKUS twice daily or matching placebo. The primary efficacy endpoint was AM pre-dose FEV 1 and secondary endpoints included other measures of lung function, rescue albuterol use, health status and exacerbations. Results: The addition of FSC to TIO significantly improved lung function indices including AM pre-dose FEV 1, 2 h post-dose FEV 1, AM pre-dose FVC, 2 h post-dose FVC and AM pre-dose IC compared with TIO alone. Furthermore, this combination was superior to TIO alone in reducing rescue albuterol use. However, there were no significant differences between the treatment groups in health status or COPD exacerbations. The incidence of adverse events was similar in both groups. Conclusions: The addition of FSC to subjects with COPD treated with TIO significantly improves lung function without increasing the risk of adverse events. NCT00784550.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalRespiratory Medicine
Issue number1
StatePublished - Jan 2012

Bibliographical note

Funding Information:
This study (ADC111114, NCT01013948) was funded by GlaxoSmithKline, Research Triangle Park, NC. The authors did not receive any money for writing the manuscript. These data have been presented in part at the 2010 Annual meeting of the American College of Chest Physicians in Vancouver, BC.


  • Bronchodilator
  • COPD
  • Inhaled corticosteroid
  • Long-acting beta -agonist
  • Triple therapy


Dive into the research topics of 'Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD'. Together they form a unique fingerprint.

Cite this